Nineteen-Year Evidence on Measles-Mumps-Rubella Immunization in Mexico: Programmatic Lessons and Policy Implications

In Mexico, the measles vaccine was first introduced in 1971. The last case of measles acquired through endemic transmission was recorded in 1995. In 1998, the monovalent measles vaccine was replaced by the combined measles-mumps-rubella (MMR) vaccine. The MMR vaccination schedule consists of two doses: the first is administered at 12 months of age, and the second is administered at either 18 months or 6 years of age.

A retrospective analysis was conducted using secondary data from 2006 to 2024. Vaccine procurement and administration records from IMSS, ISSSTE, and SSA were reviewed to evaluate the performance of both the MMR and MR programs, focusing particularly on the trends in coverage and data consistency across institutions.

The analysis revealed persistent inconsistencies between vaccine procurement and administration for both the MMR and MR vaccines across all institutions. Several years exhibited notable mismatches, including surpluses and deficits in the administered doses relative to their procurement. Between 2006 and 2024, only 69 million of the 91.6 million required MMR doses were administered in Mexico, leaving a deficit of approximately 22.5 million doses (25% of the target population). For MR, a cumulative deficit of approximately 24.6 million procured but unadministered doses was identified. National coverage remained suboptimal, with significant variability across years and institutions. Comparisons with WHO and ENSANUT data indicated marked discrepancies. The seroprevalence findings, along with the 2025 measles outbreak, confirm significant gaps in immunity.

This study highlights systemic challenges in Mexico's MMR vaccination program, including inconsistencies in vaccine procurement, administration, and reported coverage across institutions. Overestimated official MMR coverage rates and unclear target definitions for MR contribute to program inefficiencies and missed vaccination opportunities. The resurgence of measles in 2025, along with persistently high incidences of mumps, aligns with the observed immunity gaps, although a direct causal relationship cannot be established from this study. These findings are consistent with previous national studies and seroprevalence data.

Despite limitations in the data, this study effectively evaluated the performance of Mexico's MMR vaccination program, identifying critical gaps in coverage, data reliability, and operational alignment. The findings underscore the need for improved procurement planning, harmonized coverage estimates, and robust monitoring systems. To address the existing gaps in immunity, catch-up campaigns should prioritize the use of the MMR vaccine over MR. Strengthening nominal coverage tracking and implementing evidence-based strategies are essential to restoring public trust and maintaining the goals of measles elimination.